Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination With Continuous Intravenous Doses of PRI-724, a CBP/ beta-Catenin Inhibitor, to Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy With FOLFIRINOX (or FOLFOX)

Trial Profile

Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination With Continuous Intravenous Doses of PRI-724, a CBP/ beta-Catenin Inhibitor, to Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy With FOLFIRINOX (or FOLFOX)

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Gemcitabine (Primary) ; PRI 724 (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors PRISM Pharma Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Jun 2015 Planned End Date changed from 1 Jun 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top